Medicare targets popular weight loss drugs Ozempic, Wegovy

Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Medicare announces 15 new drugs up for price negotiations, including Ozempic
The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.
US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
Ozempic among drugs targeted in upcoming Medicare price negotiations
Novo Nordisk’s blockbuster diabetes and weight-loss drugs Ozempic and Wegovy are among a group of 15 drugs set to be affected by the next round of US government price negotiations by Medicare. The group of drugs accounted for about $41bn in annual spending by Medicare,
Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.
Ozempic, Wegovy among drugs subject to Medicare price controls
The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.
Becker's Hospital Review3d
New weight loss pill to be approved by early 2026: Eli Lilly
Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.
Medscape1mon
A New Weight Loss Drug With No Side Effects? Yes…So Far
Another big one is muscle loss. A new ... weight loss,” Gerhart-Hines said. He explained that GLP-1 agonists don’t work quite as well for weight loss in people with diabetes because the ...
UPI27d
FDA approves weight-loss drug Zepbound to treat sleep apnea
21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been ... weight-loss medications more than doubled between 2022 and 2023. Meanwhile, they have also been ...
STAT7d
In debate over obesity medications, FDA shifts toward importance of drugs in subtle ways
For years now, companies behind weight loss drugs like ... It seems the Food and Drug Administration has now shifted its perspective, too. This week, amid a slew of new recommendations that ...
Atlanta Journal-Constitution1mon
Weight loss drugs credited with decline in U.S. obesity rates
In a public health breakthrough, U.S. obesity rates have decreased for the first time in more than a decade, with new weight loss medications potentially playing a role in the turnaround ...
New York Post10d
Ozempic 3.0? This drug causes the greatest weight loss — by far
They investigated 12 medications — three that the US Food and Drug Administration (FDA) has approved for weight loss and nine it hasn’t. The drugs mimic GLP-1, a hormone the body naturally ...
Daily Mail23d
New birth Pill that can help you lose weight
A new contraceptive pill which does not cause weight gain, headaches or mood swings is to be launched in Britain next month. Its makers claim the pill, called Yasmin, can also improve skin and ...
Weight-loss drug developer Metsera reveals wider loss in US IPO filing
(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a ...